Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site

LOS ANGELES, May 26, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced the commencement of CAR-T NXC-201 Engineering Batches at its U.S. Manufacturing Site. These U.S. engineering batches will support the planned U.S. expansion of the Company’s ongoing Phase 1b/2a NEXICART-1 (NCT04720313) study of its novel BCMA-targeted chimeric antigen receptor T (car-T) cell therapy NXC-201.  This manufacturing milestone represents a crucial next step in transferring the Company’s existing CAR-T GMP manufacturing process to the United States following the selection of a U.S. GMP manufacturer in February 2023.

Read more at globenewswire.com